271results about "Saccharide compounds with non-saccharide radicals" patented technology

The invention is directed to compounds of formula (I) wherein X is O or NH; R' is a hydrocarbon chain; R<3 >and R<4 >are hydrogen, OH or a monosaccharide; R<5 >is hydrogen or a monosaccharide; Q' is optionally present and may be a C1-10 hydrocarbon; X' is optionally present and may be O, S or NR<8>; and Q<3 >may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).

Disclosed is an analgesic agent for a non-inflammatory pain disease, which comprises a sialic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The sialic acid which is an active ingredient for the agent has an analgesic effect on a disease model animal of neurogenic pain which is a non-inflammatory pain. Therefore, the analgesic agent is useful as a pharmaceutical agent for the treatment of a non-inflammatory pain disease such as a neurogenic pain disease, e.g. trigeminal neuralgia, postherpetic neuralgia, entrapment neuropathy, complex regional pain syndrome, diabetic neuropathy, traumatic neuropathy, phantom limb pain, central pain after spinal cord injury or stroke, and neuropathy caused by pharmacotherapy or radiation therapy, or the like.

The present invention provides a process for preparing a sugar chain asparagine derivative. According to the process, various isolated sugar chain asparagine derivatives useful in the field of the development of pharmaceuticals and the like can be conveniently obtained in a large amount as compared to that of the prior art. The present invention also provides a process for preparing a sugar chain asparagine and a process for preparing a sugar chain via a step for preparing a sugar chain asparagine derivative. The present invention further provides a novel sugar chain asparagine derivative, a sugar chain asparagine and a sugar chain.

A process for obtaining one or more than one salt of an organic acid(s), or organic acid(s), from an aqueous sugar stream comprising one or more than one mineral acid and the organic acid(s) is provided. The process comprises introducing the aqueous sugar stream to a separation system comprising one or more beds of anion exchange resin and obtaining a stream therefrom comprising the sugar. The one or more beds of anion exchange resin are then regenerated in one or more stages to produce at least one product stream comprising the organic acid, a salt of the organic acid, or a combination thereof, and a separate outlet stream comprising the mineral acid, a salt of the mineral acid, or a combination thereof. The product stream is then recovered. The separation may be conducted with two separation units, or using a single anion exchange unit.

C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and / or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and / or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and / or keratinocytes.

Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.

The present invention provides methods for producing sialyloligosaccharides in situ in dairy sources and cheese processing waste streams, prior to, during, or after processing of the dairy source during the cheese manufacturing process. The methods of the present invention use the catalytic activity of alpha(2-3) trans-sialidases to exploit the high concentrations of lactose and alpha(2-3) sialosides which naturally occur in dairy sources and cheese processing waste streams to drive the enzymatic synthesis of alpha(2-3) sialyllactose. alpha(2-3) sialyloligosaccharides produced according to these methods are additionally encompassed by the present invention. The invention also provides for recovery of the sialyloligosaccharides produced by these methods. The invention further provides a method for producing alpha(2-3) sialyllactose. The invention additionally provides a method of enriching for alpha(2-3) sialyllactose in milk using transgenic mammals that express an alpha(2-3) trans-sialidase transgene. The invention also provides for recovery of the sialyllactose contained in the milk produced by this transgenic mammal either before or after processing of the milk. Transgenic mammals containing an alpha(2-3) trans-sialidase encoding sequence operably linked to a regulatory sequence of a gene expressed in mammary tissue are also provided by the invention.

Compounds and methods are provided for treating patients suffering from health condition associated with an expression state of a gene such as fertility disorders, cancer, proliferative diseases, vascular diseases, wounds requiring therapeutic intervention, inflammation, and pulmonary disorders by administering to said patient a compound capable of modulating egr-1 and / or an egr-1 response element consensus sequence thereby altering the expression state of said gene. Also described are new methods for screening compounds to identify effectors of egr-1 and / or egr-1 consensus sequence elements and methods for treating patients by administering such effectors to modulate egr-1 and / or egr-1 consensus sequences to thereby modify expression of genes associated therewith to in turn treat diseases or other physiological conditions associated with such gene expression.

An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and / or in close proximity thereto. The cleavable group or moiety is cleaved under selective conditions including change of chemical, physical or biological environment and is preferably cleaved enzymatically in a biological environment such as the brain or the blood. Vesicles or liposomes made from said amphiphilic compounds are suitable for delivery of a therapeutic substance or a diagnostic agent specifically to a target organ or tissue, or for delivery of a nucleic acid for gene therapy.

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

The invention relates to a method for preparing bagasse dissolving pulp and pre-extracting hemicellulose and products thereof; the method comprises the following steps: bagasse preparation which comprises the steps of depithing and washing; prehydrolysis which is carried out in a globe digester or a hydrolysis boiler; wherein, the process conditions are as follows: in the process for depithing and oven-drying bagasse, the solid-to-liquid ratio is 1:0.4-8.0, the hydrolysis temperature is 100-200 DEG C, the hydrolysis time is 15-240min, the pH value of the end point of hydrolysis is 2-5; in the process of the solid-to-liquid separation and washing, the filtrate is collected to prepare extracting solution; dissolving pulp is prepared by residue alkali method. By adopting the method, bagasse dissolving pulp and bagasse extracting solution which is used to prepare oligosaccharides are obtained. Most of pentosan in bagasse can be extracted by controlling the process conditions of the prehydrolysis, the technical route and the process conditions have strong pertinence so that the reactivity and the uniformity of bagasse dissolving pulp can be improved; by improving the traditional dissolving pulp alkali method for pulping, bagasse biorefinery based on dissolving pulp pulping can be realized in engineering so that the production costs for preparing bagasse dissolving pulp and pre-extracting hemicellulose are reduced.

The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and / or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.

The present invention provides nitrogen-containing fused cyclic derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula one of R1 and R4 represents a group represented by the following general formula (S) (in which R5 and R6 represent H, OH, a halogen atom, etc.; Q represents an alkylene group etc.; and ring A represents an aryl group etc.), and the other represents H, OH, an amino group, etc.; R2 and R3 represent H, OH, an amino group, a halogen atom, and an optionally substituted alkyl group, etc.; A1 represents O, S, etc.; A2 represents CH or N; G represents a group represented by the following general formula (G-1) or (G-2) (E1 represents H, F or OH; and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

The invention discloses a method for extracting sialic acid from bird nests by means of crystallization. The method comprises the steps of soaking the bird nests with deionized water and removing impurities; then pulping and crushing, heating under a high pressure, centrifuging, drying, dissolving and crystallizing to obtain the sialic acid. According to the method disclosed by the invention, hydrolysis of the glycoproteins of the bird nests is accelerated through serious heating by means of high-pressure heating, and the combined-state sialic acid is converted to a free-state sialic acid; the high-pressure heating avoids the introduction of other ingredients, thereby simplifying the subsequent separation and purification steps; the sialic acid crude product obtained by freeze-drying is prepared into alcohol-saturated solution by virtue of the property that the sialic acid is slightly dissolved in alcohol but proteins and polysaccharides are insoluble in alcohol, and therefore on one hand, the impurities such as alcohol-insoluble proteins and polysaccharides are removed, on the other hand, the solvent polarity is changed by adding a non-polar solvent, and sialic acid crystals are obtained according to the different seperation sequences of the sialic acid and the impurities. According to the method disclosed by the invention, sialic acid extraction steps are simplified, and industrial pollution is reduced.

The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and / or hexosamine, containing nitro groups —ONO2 covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and / or hexosamine, with subsituents containing a ONO2 ? group.

This invention relates to the novel identification of myelin-associated glycoprotein ("MAG") as a potent inhibitor of neural regeneration. More particularly, this invention relates to compositions and methods useful for reversing inhibition of neural regeneration in the central and peripheral nervous system. Assays to monitor the effects of MAG on neural regeneration and to identify agents which will block or promote the inhibitory effects of MAG on neural outgrowth are provided. Screening methods for identifying such agents are also provided. This invention also relates to compositions and methods using agents that can reverse the inhibitory effects of MAG on neural regeneration. Methods for regulating and for promoting neural growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with disorders or diseases, comprising the step of administering at least one of the compositions according to this invention are provided.

The invention discloses a method for continuously separating sialic acid, wherein sialic acid is prepared through microbial fermentation by taking N-acetyl glucosamine and sodium pyruvate as substrates; fermentation liquor is processed through filtration and ultrafiltration so as to obtain sialic acid clear liquid; sialic acid clear liquid is pumped in a continuous ion exchange system provided with OH-type anion exchange resin for adsorption; deionized water is adopted for leaching; a sodium chloride solution is adopted for elution; a sodium hydroxide solution is adopted for resin regeneration; eluent containing sialic acid is collected, is leached through an ethanol water solution, and then is added with ethyl acetate for dilution crystallization; and crystals are dried under reduced pressure, so that pure sialic acid is obtained. The separation and purification method is simple, convenient and feasible, achieves good effect and low running cost, and can implement the separation from kilogram class to ton class according to the separation amount; and in addition, products that are obtained by adopting the method gain excellent results on yield coefficient and product quality, and the product quality is ensured..

The invention relates to a bagasse alkaline pulping method by pre-extracting hemicellulose and a product thereof; the method includes the following steps of: preparing bagasse: depithing and washing the bagasse; pre-extraction, in which the extracted solvent is sodium hydroxide solution and the technical condition comprises an alkaline content of 1-8percent, a solid-to-liquid ratio of 1:2.5-8.0, extraction temperature of 80-180 DEG C, heating-up time of 10-120 minutes, holding time of 0-120 minutes, a pH value of 4.5-6.9 at a reaction end point, and the pressure of saturated steam pressure at corresponding temperature; liquid solid separation and washing: collecting filtrate to produce extract; and preparing the pulp by residue alkaline process. In the invention, bagasse extract capable of extracting xyio-oligosacchandes, and the like and bagasse rough pulp for preparing whitened chemical pulp can be obtained; with a pre-extraction procedure added before stewing, the unscreened yield and hardness of bagasse are equivalent to that of pure pulping without pre-extraction by controlling the pre-extraction and stewing technical condition; bagasse biological refining on a pulping basis is realized; and the cost for pulping and pre-extracting hemicellulose is reduced, thereby saving resources.

The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.

The invention relates to sialic acid and an extraction method thereof and belongs to the technical field of sialic acid extraction. The method comprises the step of subjecting polysialic acid to a hydrolysis reaction for 10 to 40 minutes on a super-strength solid acid fixed bed. According to the sialic acid and the extraction method thereof, reaction time of the polysialic acid on the super-strength solid acid fixed bed is controlled to reduce degradation of the sialic acid, so that the purity of the sialic acid prepared from the polysialic acid through hydrolysis reaches 98% or more, and theyield of the sialic acid reaches 70% or more.

The invention relates to an oligosaccharide metallic compound. The compound is characterized in that sugar residues of the compound consist of alpha-1, 4-L-guluronic acid; the weight average molecular weight of the compound is less than or equal to 12kD; and a molecular general formula of the compound is (C6H7O6)nCrm, wherein n is equal to 1 to 54, m is equal to 1 to 27 and the mass percentage of trivalent chromium is 0.1 to 12 percent. The preparation of the compound comprises the following steps: slowly adding chromic salt and dilute alkaline aqueous solutions in oligoguluronic acid aqueous solution under the conditions that pH is equal to 5 to 10 and temperature is between 40 and 80 DEG C; after stopping adding dilute alkaline and chromic salt aqueous solutions, carrying out heat-insulation reaction for 1 to 3h; carrying out filtration and precipitating the filtrate by ethanol with the volume 3 to 5 times that of the filtrate; carrying out static, precipitation and centrifugation; and collecting and washing the precipitate by using anhydrous ethanol to obtain the compound after drying. The oligosaccharide metallic compound has the advantages that because the raw materials are derived from marine natural products, the compound has abundant resources, easy industrialization, high safety, unique structure and ideal oral absorption and particularly integrates the advantages of marine oligosaccharide and trivalent chromium; and the compound not only has the functions of preventing insulin resistance and adjusting sugar and fat metabolism disturbance, but also has broad market and application prospects particularly in the prevention and treatment of diabetes II.

The invention discloses a method for separating hyaluronate tetrasaccharide from hyaluronate hexasaccharide, and belongs to the technical field of bioengineering. The method comprises the following steps: adopting Q Sepharose fast flow as an ion exchanger, Tris-HCl with the pH value of 8-9 as an equilibrium liquid, and 0.125 M NaCl with the pH value of 8, performing linear gradient elution to separate hyaluronate tetrasaccharide from hyaluronate hexasaccharide, and desalting to obtain pure products of hyaluronate tetrasaccharide and hyaluronate hexasaccharide.

The invention discloses sialic acid and an extraction method thereof, and belongs to the technical field of sialic acid extraction. Sialic acid solution obtained by pretreating a sialic acid monomer source is subjected to alkaline neutralization, concentration purification, heating concentration, acidification and crystallization to obtain the sialic acid. The extraction method of the sialic acidhas the advantages of short working time, low cost and high yield and purity of the extracted sialic acid.

The invention relates to a novel admixture for mineral binders, composed of a composition containing at the same time a sugar or an oxidized sugar and a hydrogenated sugar. The oxidized sugar may consist, in particular, of gluconic acid or one of its salts or an oxidized starch hydrolysate. The hydrogenated sugar may consist in particular of maltitol, sorbitol, mannitol, xylitol, arabitol, or a hydrogenated starch hydrolysate containing at least 40% by weight of maltitol. Within the admixture, this composition may be combined with conventional admixtures such as phosphates, borates, or amines. The combination of a sugar or an oxidized sugar and a hydrogenated sugar within this composition makes it possible to obtain synergistic effects, particularly in terms of plasticity and mechanical properties of the mineral binders. The admixtures claimed may be used equally well for admixing with cements, raw materials for cements as for admixing with mortars, slurries and concretes. They may also be used in other sectors such as, for example, the plaster industry, particularly as complexing agents or hydration or dehydration controllers.